Business Context and Reporting Period
Company: Disc Medicine, Inc. (IRON)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2024
Business Overview: Disc Medicine is a clinical-stage biopharmaceutical company focused on developing novel treatments for serious hematologic diseases. The company has no products approved for commercial sale and has not generated any revenue from product sales. Its pipeline includes bitopertin (for erythropoietic porphyrias and Diamond-Blackfan Anemia), DISC-0974 (for anemia of myelofibrosis and chronic kidney disease), and DISC-3405 (for polycythemia vera).
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9 Months 2024 | 9 Months 2023 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(26,599) | $(14,122) | $(79,900) | $(52,850) |
| Net Loss Per Share (Basic & Diluted) | $(0.89) | $(0.58) | $(2.98) | $(2.45) |
| Operating Expenses | $32,856 | $18,958 | $95,170 | $61,411 |
| Research & Development (R&D) | $24,685 | $14,419 | $71,874 | $46,699 |
| General & Administrative (G&A) | $8,171 | $4,539 | $23,296 | $14,712 |
| Interest Income | $6,362 | $4,843 | $15,454 | $10,120 |
| Cash, Cash Equivalents & Marketable Securities | $487,363 | $360,382 | $487,363 | $360,382 |
| Accumulated Deficit | $(268,545) | $(165,066) | $(268,545) | $(165,066) |
Note: Cash, Cash Equivalents & Marketable Securities for Q3 2024 is the sum of Cash ($192,638) and Marketable Securities ($294,725) as of September 30, 2024.
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss for the nine months ended September 30, 2024, increased by $27.1 million compared to the same period in 2023, primarily driven by higher operating expenses.
- R&D Expense Growth: R&D expenses increased by $25.2 million (54%) year-over-year for the nine-month period. This was due to increased clinical study and drug manufacturing activity for bitopertin and DISC-0974, as well as higher personnel-related costs including stock-based compensation.
- G&A Expense Growth: G&A expenses increased by $8.6 million (58%) year-over-year, primarily due to higher headcount and increased stock-based compensation.
- Interest Income: Interest income increased by $5.3 million for the nine-month period due to larger cash and marketable securities balances and higher interest rates.
- Capital Raise: In June 2024, the company completed an underwritten offering of 4,944,000 shares, raising net proceeds of $172.5 million. Additionally, $14.8 million was raised through at-the-market offerings in the first quarter of 2024.
Guidance, Outlook, Risks, and Unusual Items
- Outlook & Liquidity: Management expects existing cash, cash equivalents, and marketable securities ($487.4 million as of Sept 30, 2024) to fund operations for at least 12 months. Following a subsequent event in November 2024, the company entered a loan agreement providing up to $200 million in senior secured term loans, with an initial $30 million advance funded on November 6, 2024. Management believes these resources will fund operations well into 2027.
- Clinical Pipeline Updates:
- Bitopertin: Topline data from the AURORA Phase 2 trial in EPP was presented in April 2024. The company plans to initiate the APOLLO Phase 3 trial by mid-2025. The FDA agreed that reduction of protoporphyrin IX (PPIX) could serve as a surrogate endpoint for potential accelerated approval.
- DISC-0974: Interim data from Phase 1b/2 trials in anemia of myelofibrosis and non-dialysis dependent CKD were presented in 2024.
- DISC-3405: Interim data from the Phase 1 single-ascending dose trial in healthy volunteers was presented in June 2024.
- Risks:
- Capital Requirements: The company has incurred significant losses since inception and expects to continue doing so. It will need substantial additional funding to complete clinical trials and commercialization.
- Regulatory Approval: No products are approved. Success depends on completing clinical trials and obtaining regulatory approval, which is uncertain.
- Third-Party Reliance: The company relies on third parties for clinical trials and manufacturing, introducing risks of delays or quality issues.
- Intellectual Property: The company relies on in-licensed IP from Roche, AbbVie, and Mabwell. Failure to maintain these licenses or defend against challenges could harm the business.
- Unusual Items: The filing notes a subsequent event regarding the Hercules Loan Agreement (Note 17), which was not reflected in the September 30, 2024 balance sheet but significantly impacts future liquidity.
Key Facts for Investor Verification
- Cash Runway: Verify the company's ability to fund operations into 2027 based on the $487.4 million cash position plus the new $200 million credit facility.
- APOLLO Trial Timeline: Confirm the initiation date of the APOLLO Phase 3 trial for bitopertin, currently planned for mid-2025, and the status of discussions with the FDA regarding the accelerated approval pathway.
- Debt Covenants: Review the specific covenants in the Hercules Loan Agreement, particularly the minimum cash covenant effective January 1, 2027, and the potential for payment-in-kind (PIK) interest.
- Stock-Based Compensation: Monitor the impact of stock-based compensation on future expenses, which totaled $12.5 million for the nine months ended September 30, 2024, and has $51.9 million of unrecognized expense remaining.
- License Milestones: Track progress toward development and regulatory milestones for in-licensed assets (Roche, AbbVie, Mabwell) which could trigger significant future payments.